Amgen (AMGN) has been a market buzz owing to its
28% one-year share price gains, encouraging a reassessment of the biotech company's position. The company has actively acquired
Dark Blue Therapeutics, bolstering its oncology pipeline. This acquisition, along with the
DISCO Oncology deal and analysts' optimism, has revalued Amgen's standing in the market. Notably,
HSBC has turned increasingly bullish on Amgen into 2026. Following Q3 earnings, there has been a steadfast interest in the company’s stock, evidenced by several share acquisitions by reputable firms such as
Nepsis Inc.,
Oregon Public Employees Retirement Fund, and
HB Wealth Management LLC. Improving its value proposition, Amgen has taken action with the US government to
lower the cost of medicines for American patients and has declared an increase in its
dividend to $2.52. Amidst this positive operational landscape, Amgen's stock has seen a few intermittent declines, despite overall market improvements. Amgen also plans to expand its Puerto Rico facility by investing
$650M, anticipating job creation.
Amgen AMGN News Analytics from Wed, 23 Jul 2025 07:00:00 GMT to Sat, 10 Jan 2026 12:07:28 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 3
